{"entity":{"id":"cbx-250","kind":"drug","name":"CBX-250","aka":[],"tldr":"CBX-250 is an experimental TCR-mimetic T cell engager from Crossbow Therapeutics, in phase 1 trials for relapsed or refractory acute myeloid leukaemia, higher-risk myelodysplastic syndrome and chronic myelomonocytic leukaemia and other cancers.","summary":"CBX-250 is a TCR-mimetic T cell engager (T-Bolt) from Crossbow Therapeutics. A T cell engager whose TCR-mimetic antibody arm recognises a cathepsin G peptide presented on HLA, abundant on leukaemia cells but not normal cells, and pulls T cells onto them. Given under the skin. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia, higher-risk myelodysplastic syndrome, chronic myelomonocytic leukaemia and chronic myeloid leukaemia. ClinicalTrials.gov registers it in one study linked below. CROSSCHECK-001 phase 1 NCT06994676 recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Crossbow Therapeutics: crossbowtx.com","url":"https://www.crossbowtx.com/press-release-09-16-25"},{"label":"Crossbow Therapeutics: crossbowtx.com","url":"https://www.crossbowtx.com/"},{"label":"Crossbow Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06994676"},{"label":"ClinicalTrials.gov: trials of CBX-250","url":"https://clinicaltrials.gov/search?intr=CBX-250"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds-higher-risk","cmml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["crossbow-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06994676"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CBX-250","modality":"TCR-mimetic T cell engager (T-Bolt)","mechanism":"A T cell engager whose TCR-mimetic antibody arm recognises a cathepsin G peptide presented on HLA, abundant on leukaemia cells but not normal cells, and pulls T cells onto them. Given under the skin.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cbx-250/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"}],"company":[{"id":"crossbow-therapeutics","kind":"company","name":"Crossbow Therapeutics","route":"/companies/crossbow-therapeutics/"}],"trial":[{"id":"nct06994676","kind":"trial","name":"A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias","route":"/trials/nct06994676/"}]}}